Mizuho upgraded shares of Teva Pharmaceutical Industries (NYSE:TEVA) from a neutral rating to a buy rating in a report issued on Tuesday, MarketBeat reports. They currently have $23.00 price objective on the stock, up from their prior price objective of $19.12.

A number of other research firms have also recently issued reports on TEVA. Wells Fargo & Co cut Teva Pharmaceutical Industries from a market perform rating to an underperform rating and cut their price target for the company from $19.58 to $17.00 in a report on Friday, January 5th. Gabelli reaffirmed a buy rating on shares of Teva Pharmaceutical Industries in a report on Wednesday, September 13th. BidaskClub raised Teva Pharmaceutical Industries from a strong sell rating to a sell rating in a report on Wednesday, September 13th. Citigroup raised Teva Pharmaceutical Industries from a neutral rating to a buy rating and set a $24.00 price target for the company in a report on Thursday, January 4th. Finally, Leerink Swann began coverage on Teva Pharmaceutical Industries in a report on Tuesday, January 2nd. They issued an underperform rating and a $15.00 price target for the company. Seven analysts have rated the stock with a sell rating, sixteen have issued a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has an average rating of Hold and an average price target of $21.42.

Teva Pharmaceutical Industries (NYSE TEVA) traded up $0.67 during trading on Tuesday, hitting $20.04. The company had a trading volume of 32,640,576 shares, compared to its average volume of 25,680,000. The company has a debt-to-equity ratio of 1.20, a current ratio of 0.96 and a quick ratio of 0.66. Teva Pharmaceutical Industries has a fifty-two week low of $10.85 and a fifty-two week high of $37.94. The company has a market capitalization of $20,280.00, a PE ratio of -3.41, a price-to-earnings-growth ratio of 1.36 and a beta of 0.54.

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, December 12th. Shareholders of record on Tuesday, November 28th were issued a dividend of $0.085 per share. The ex-dividend date was Monday, November 27th. This represents a $0.34 annualized dividend and a yield of 1.70%. Teva Pharmaceutical Industries’s dividend payout ratio is currently -12.27%.

Hedge funds have recently made changes to their positions in the company. Exane Derivatives bought a new stake in shares of Teva Pharmaceutical Industries in the 3rd quarter valued at about $571,000. Korea Investment CORP increased its stake in shares of Teva Pharmaceutical Industries by 14.3% in the 3rd quarter. Korea Investment CORP now owns 244,774 shares of the company’s stock valued at $4,308,000 after acquiring an additional 30,674 shares during the last quarter. Private Capital Management Inc. increased its stake in shares of Teva Pharmaceutical Industries by 51.3% in the 3rd quarter. Private Capital Management Inc. now owns 26,100 shares of the company’s stock valued at $459,000 after acquiring an additional 8,850 shares during the last quarter. Financial Counselors Inc. increased its stake in shares of Teva Pharmaceutical Industries by 28.8% in the 3rd quarter. Financial Counselors Inc. now owns 181,130 shares of the company’s stock valued at $3,188,000 after acquiring an additional 40,531 shares during the last quarter. Finally, Lockheed Martin Investment Management Co. bought a new stake in shares of Teva Pharmaceutical Industries in the 3rd quarter valued at about $317,000. 51.98% of the stock is owned by institutional investors.

TRADEMARK VIOLATION NOTICE: This news story was originally published by Watch List News and is the sole property of of Watch List News. If you are reading this news story on another site, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be accessed at https://www.watchlistnews.com/teva-pharmaceutical-industries-teva-lifted-to-buy-at-mizuho/1801927.html.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.